Premium
Metabolite Identification via LC‐SPE‐NMR‐MS of the In vitro Biooxidation Products of a Lead mGlu5 Allosteric Antagonist and Impact on the Improvement of Metabolic Stability in the Series
Author(s) -
Ceccarelli Simona M.,
Schlotterbeck Götz,
Boissin Patrick,
Binder Martin,
Buettelmann Bernd,
Hanlon Steven,
Jaeschke Georg,
Kolczewski Sabine,
Kupfer Ernst,
Peters JensUwe,
Porter Richard H. P.,
Prinssen Eric P.,
Rueher Marianne,
Ruf Iris,
Spooren Will,
Stämpfli Andreas,
Vieira Eric
Publication year - 2008
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.200700203
Subject(s) - chemistry , metabotropic glutamate receptor 5 , lead compound , metabolite , metabolomics , allosteric regulation , metabotropic glutamate receptor , combinatorial chemistry , chromatography , biochemistry , agonist , in vitro , receptor
Detailed information on the metabolic fate of lead compounds can be a powerful tool for an informed approach to the stabilization of metabolically labile compounds in the lead optimization phase. The combination of high performance liquid chromatography (HPLC) with nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) has been used to give comprehensive structural data on metabolites of novel drugs in development. Recently, increased automation and the embedding of on‐line solid‐phase extraction (SPE) into a integrated LC‐SPE‐NMR‐MS system have improved enormously the detection limits of this approach. The new technology platform allows the analysis of complex mixtures from microsome incubations, combining low material requirements with relatively high throughput. Such characteristics make it possible to thoroughly characterize metabolites of selected compounds at earlier phases along the path to lead identification and clinical candidate selection, thus providing outstanding guidance in the process of eliminating undesired metabolism and detecting active or potentially toxic metabolites. Such an approach was applied at the lead identification stage of a backup program on metabotropic glutamate receptor 5 (mGlu5) allosteric inhibition. The major metabolites of a lead 5‐aminothiazole‐4‐carboxylic acid amide 1 were synthesized and screened, revealing significant in vitro activity and possible involvement in the overall pharmacodynamic behavior of 1 . The information collected on the metabolism of the highly active compound 1 was pivotal to the synthesis of related compounds with improved microsomal stability.